CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
Can-Fite BioPharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$1.89+0.13 (+7.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.13 (−81.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Can-Fite BioPharma Ltd. saw revenue fall 39.9% to $405.00K over fiscal 2025. Free cash flow was -$8.95M.
Revenue
$405.00K
-39.9% vs. a year earlier
Operating income
-$9.95M
FY2025
Free cash flow
-$8.95M
FY2025
EPS, diluted
-$5.97
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $405.00K
- Net income
- -$9.83M
- EPS, diluted
- -$5.97
- Free cash flow
- -$8.95M
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$405.00K-39.9% YoY
Operating income
-$9.95M
Net income
-$9.83M
EPS, diluted
-$5.97
Free cash flow
-$8.95M
Reported period